CST BLOG

The official blog of Cell Signaling Technology, where we discuss what to expect from your time at the bench, share tips, tricks, and information.

CST Blog

Read More →

CAR T Cell Detection: Anti-CAR Linker Antibodies for Whitlow/218 & G4S

CST® anti-CAR linker antibodies won The Innovation Award from CiteAb in 2023. Read on to learn why! ...
Amrik Singh, PhD Nov 8, 2022

Therapeutic Approaches for the Treatment of Multiple Myeloma

Multiple myeloma is a cancer of plasma cells that is treatable, but not curable. In this blog, we re...
Andrea Tu, PhD Jul 2, 2022

Novel Therapeutic Approaches for Diffuse Large B-Cell Lymphoma

Lymphoma is a cancer of the lymphatic system, a principal part of the body’s immune system. Lymphoma...
Andrea Tu, PhD May 11, 2022

Immunology: Immunophenotyping Using Flow Cytometry or IHC

In the field of immunology and immuno-oncology, immunophenotyping is a technique that uses antibodie...
Chris Sumner Jun 30, 2021

Targeting TIGIT for Cancer Immunotherapy & T Cell Exhaustion

The evolution of solid tumor cancer treatment has historically centered on a tripartite approach tha...
Tamar Aprahamian, PhD Feb 17, 2021

Immunology: What are toll-like receptors and how do they invoke tumor tolerance?

Toll-like receptors (TLRs) are transmembrane receptors that play a critical role in innate immune re...
Tamar Aprahamian, PhD Jun 10, 2020

Imaging Mass Cytometry: Endless Possibilities to Understand the Microenvironment of Disease

Understanding the microenvironment of disease is critical. Targeted cancer therapies may not be effe...

Demystifying Antibody Panel Design for Multiplex IHC

In recent years, immune checkpoints in the tumor microenvironment have been under intense study. If ...
Jen Z Oct 10, 2018

Research Trends in Macrophage Plasticity

It’s an exciting time for immuno-oncology research, as potential predictive biomarkers from an expan...
Kenneth Buck, PhD Sep 19, 2018

Targeting B-Cell Maturation Antigen (BCMA) Holds Promise for Multiple Myeloma Treatment

Multiple myeloma (MM) is a type of hematopoietic malignancy characterized, in part, by bone pain, an...
Amrik Singh, PhD Aug 8, 2018

GPNMB: A Promising Immunotherapeutic Target for Triple Negative Breast Cancer

The last few years have witnessed several breakthroughs in the immuno-oncology space. Treatments tha...
Amrik Singh, PhD Apr 4, 2018

      Categories

      25-JRY-19751_TrialSize_Blog Listing Ad

      CST Newsletter

      Popular Posts

      Recent Posts
      CST blog Cellular Landscape Footer